Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Richard A. Marlar"'
Autor:
Richard A. Marlar
Publikováno v:
Seminars in Thrombosis and Hemostasis.
Thrombophilia is a complex disease process, clinically manifesting in various forms of venous thromboembolism. Although both genetic and acquired (or environmental) risks factors have been reported, the presence of a genetic defect (antithrombin [AT]
Publikováno v:
The Journal of Applied Laboratory Medicine. 7:794-802
Background One of the most complex risk factors for the laboratory assessment of thrombophilia is Protein S (PS). The testing algorithm for PS employs the plasma-based assays of free PS antigen, total PS antigen, and PS activity creating a complex di
Autor:
Richard A. Marlar
Publikováno v:
Methods in Molecular Biology ISBN: 9781071631744
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47215738521bb3def98eaa8e0cbf3900
https://doi.org/10.1007/978-1-0716-3175-1_10
https://doi.org/10.1007/978-1-0716-3175-1_10
Autor:
Josefin Ahnström, Björn Dahlbäck, Elisabetta Castoldi, Richard A. Marlar, Herm Jan M. Brinkman
Publikováno v:
Journal of Thrombosis and Haemostasis, 19(1), 281-286. Wiley
Hereditary deficiencies of protein S (PS) increase the risk of thrombosis. However, assessing the plasma levels of PS is complicated by its manifold physiological interactions, while the large inter-individual variability makes it problematic to esta
Publikováno v:
Journal of Thrombosis and Haemostasis. 18:271-277
Inherited protein C (PC) deficiency increases risk of venous thromboembolism (VTE) by 5 to 10-fold in thrombosis-prone families; however, heterozygous PC deficiency alone does not determine that a subject has thrombophilia. Protein C deficient subjec
Publikováno v:
International journal of laboratory hematologyREFERENCE. 44(2)
INTRODUCTION Management of hemophilia A has changed significantly in the past few years with the expansion of new and/or modified products as treatment options. Unfortunately, many of the standard factor VIII assays do not always accurately measure a
Publikováno v:
European Journal of Haematology
Treatment of haemophilia A/B patients comprises factor VIII (FVIII) or factor IX (FIX) concentrate replacement therapy, respectively. FVIII and FIX activity levels can be measured in clinical laboratories using one‐stage activated partial thrombopl
Autor:
Richard A. Marlar, Robert C. Gosselin
Publikováno v:
Seminars in Thrombosis and Hemostasis. 45:433-448
Many preanalytical variables may affect the results of routine coagulation assays. While advances in laboratory instrumentation have partially addressed the laboratory's ability to recognize some of these variables, there remains an increased relianc
Publikováno v:
International Journal of Laboratory Hematology. 41:162-169
In the coagulation laboratory, much emphasis has been placed on rapid and accurate testing; however, spurious results that are inaccurate and do not reflect the actual status of the patient can potentially lead to an incorrect diagnosis and altered i
Autor:
Steve Kitchen, Dorothy M. Adcock, Ray Dauer, Ann‐Helen Kristoffersen, Giuseppe Lippi, Ian Mackie, Richard A. Marlar, Sukesh Nair
Publikováno v:
International journal of laboratory hematologyReferences. 43(4)
This guidance document has been prepared on behalf of the International Council for Standardisation in Haematology (ICSH). The aim of the document is to provide guidance and recommendations for collection of blood samples for coagulation tests in cli